Lanabecestat - AstraZeneca
Alternative Names: AZD-3293; LY-3314814Latest Information Update: 29 Jul 2024
At a glance
- Originator Astex Pharmaceuticals; AstraZeneca
- Developer AstraZeneca; Eli Lilly and Company
- Class Antidementias; Imidazoles; Pyridines; Small molecules; Spiro compounds
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 29 Jul 2024 Discontinued - Phase-I for Alzheimer's disease (In volunteers) in United Kingdom (IV), before July 2024
- 29 Jul 2024 Discontinued - Phase-I for Alzheimer's disease in USA (PO), before July 2024
- 29 Jul 2024 Discontinued - Phase-III for Alzheimer's disease in Puerto Rico, Puerto Rico, Spain, United Kingdom, Romania, Poland, South Korea, Italy, Germany, Germany, France, Hungary, Canada, Belgium, Belgium, Japan, Australia, USA (PO), before July 2024